On Friday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Vince Holding Corp (NYSE:VNCE), DepoMed Inc. (NYSE:DEPO), ImmunoGen, Inc. (NASDAQ:IMGN), TrueCar, Inc. (NASDAQ:TRUE)
Vince Holding Corp (NYSE:VNCE), with shares declined -6.24%, closed at $16.77, hitting new 52-week low of $16.50.
DepoMed Inc. (NYSE:DEPO), with shares dropped -3.02%, settled at $24.12.
ImmunoGen, Inc. (NASDAQ:IMGN), with shares dipped -6.06%, and closed at $7.44.
TrueCar, Inc. (NASDAQ:TRUE), plummeted -3.02%, and closed at $17.37.
Latest NEWS regarding these Stocks are depicted underneath:
Vince Holding Corp (NYSE:VNCE)
Vince Holding Corp (VNCE), stated unaudited results for its fourth quarter and fiscal year 2014 ended January 31, 2015.
- Net Sales raised 7.9% for fourth quarter and 18.1% for fiscal 2014.
- Adjusted Diluted EPS raised 21.7% to $0.28 for fourth quarter and 28.8% to $0.94 for fiscal year 2014.
- Corporation provides guidance for fiscal 2015.
Jill Granoff, Chairman and Chief Executive Officer of Vince, commented, “We are proud of our strong performance in our first full year as a public corporation. We delivered record sales in 2014, with double-digit raises across all product categories and distribution channels. We are particularly happy with the exceptional growth in our retail, ecommerce, international and licensing businesses, building a platform for the future. In addition, our adjusted profits grew by nearly 29%, outpacing our sales growth, driven primarily by better than predictable gross margin expansion of 280 basis points. We were also happy with our performance in the fourth quarter, in which we achieved solid sales growth, gross margin expansion, and a nearly 22% adjusted earnings raise.”
Ms. Granoff continued, “Our customers remain passionate about our everyday luxury products, and we are seeing increasing demand on a global basis. While we are resetting our near-term growth plans in domestic wholesale for the long-term health of our brand, we have many growth opportunities in our domestic wholesale business and will continue to focus on plannedally driving our productivity within existing doors while maintaining our brand’s luxury profile. At the same time, we will aggressively pursue our other meaningful growth levers from a product, channel, and international expansion perspective to realize the full potential of the VINCE brand and deliver double-digit growth in sales and profit over the long term.”
Vince Holding Corp. is engaged in the design, merchandise, wholesale, and retail of contemporary fashion brands products. It operates through two segments, Wholesale and Direct-To-Consumer. The corporation offers a range of women’s products, such as cashmere sweaters, silk blouses, leather and suede leggings and jackets, dresses, denim, tanks, T-shirts, pants, and footwear; and men’s products comprise T-shirts, knit and woven tops, sweaters, denim, pants, blazers, outerwear, and leather jackets.
DepoMed Inc. (NYSE:DEPO)
DepoMed Inc. (DEPO), declared that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired with respect to Depomed’s pending attainment of U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals. The termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending attainment, which remains subject to completion of Depomed’s formerly declared financing and other customary closing conditions.
On January 15th, Depomed declared that it had reached a definitive contract to attain the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise comprises NUCYNTA® ER (tapentadol) extended release tablets indicated for the administration of pain, counting neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol), an immediate release version of tapentadol, for administration of moderate to severe acute pain in adults. NUCYNTA (tapentadol) oral solution is an approved oral form of tapentadol that has not been launched.
Depomed, Inc., a specialty pharmaceutical corporation, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
ImmunoGen, Inc. (NASDAQ:IMGN)
ImmunoGen, Inc. (IMGN), a biotechnology corporation that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, declared the presentations on Corporation and partner programs to be made at the forthcoming American Association for Cancer Research (AACR) annual meeting to be held April 18-22, 2015 in Philadelphia, PA. These presentations will feature scientific data for ImmunoGen and partner ADCs in addition to an array of ImmunoGen technology innovations.
“The presentations on ADCs by ImmunoGen researchers and our partners at AACR this year illustrate our ongoing commitment to advancing the ADC field to achieve better therapies for people with cancer,” commented Daniel Junius, President and CEO. “The topics span research in support of our IMGN853 and IMGN779 product candidates, preclinical data for five partner ADCs, and some of the findings from our research related to site-specific payload attachment to antibodies.”
ImmunoGen, Inc., a biotechnology corporation, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The corporation offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
TrueCar, Inc. (NASDAQ:TRUE)
Formerly on March 16, Mazda Motor Corp.’s CX-9 sport-utility vehicle, which sells at an average of 19 percent off the manufacturer’s suggested retail price (MSRP), tops the list of best savings on new vehicles in March, according to TrueCar, Inc. (TRUE), the negotiation-free car buying and selling mobile marketplace.
March has had the highest average new vehicle sales volume of any month over the past five years. The month marks the fiscal year close for Japan-based automakers and kicks off spring sales events that provide savings for consumers. Historically, the month’s final day has been the best opportunity to get the largest discount.
TrueCar, Inc. operates as an Internet-based information, technology, and communication services corporation. The corporation operates its platform on the TrueCar Website and TrueCar mobile applications. It also customizes and operates its platform for its affinity group marketing partners, counting financial institutions, membership-based organizations, and employee buying programs for large enterprises.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
